Stop chasing leads. Start meeting buyers. India is widely known as the pharmacy of the world, and the numbers back it. The world imports about $910 billion of pharmaceuticals every year (UN Comtrade, the United Nations' official and most trusted global trade database), and the biggest buyers are right where Indian generics, formulations and APIs are strongest. The United States imports $213 billion, Germany $75 billion, Switzerland $67 billion, China $42 billion, Belgium $42 billion, France $33 billion, Italy $32 billion and Japan $30 billion. India already ships about $635 million in pharmaceuticals to France alone, compounding near 13 percent a year (Ministry of Commerce, FY2025-26), one of the steadiest growth lines in the whole corridor. If you make medicines, the demand is proven and the room above your current share is large. The play now is precise: find the right buyers, in the right markets, and meet them verified.
The world buys $910 billion in medicines, led by buyers India can serve
Pharmaceutical demand is both enormous and concentrated, which is good news for an Indian exporter. Eight markets account for the lion's share of the world's $910 billion import bill (UN Comtrade). The United States sits at $213 billion, then a tight European cluster: Germany $75 billion, Switzerland $67 billion, Belgium $42 billion, France $33 billion and Italy $32 billion, with China $42 billion and Japan $30 billion completing the top tier. For a maker of generics, formulations, APIs, nutraceuticals or medical devices, that concentration means you do not need to chase a hundred countries. You need to identify the handful where your specific product, your quality certifications and your price position line up with active, growing demand, and then put your capacity in front of the people who actually buy.
India's pharma export engine: a proven foothold with headroom
India supplies under 2 percent of France's $33 billion pharmaceutical import market today (UN Comtrade), and yet that small share is already worth about $635 million and growing near 13 percent a year (Ministry of Commerce, FY2025-26). Read that the right way: a proven foothold, with a very large opportunity sitting above it. France is one example of a pattern that repeats across the European cluster. India's generics and volume reputation, strong regulatory track record and competitive cost base give Indian makers a genuine right to win more of Germany's $75 billion, Belgium's $42 billion and Italy's $32 billion as well. The growth line is steady, not a one-time spike, which is exactly the kind of market worth committing capacity to.
The target play: pick markets on growth, stability and fit
Not every big number is the right number. A market worth entering is one where demand is large, growing year on year, stable rather than volatile, and genuinely open to your product. diipl evaluates each market on the variables that decide whether you win: import tariffs, non-tariff measures (the quality, registration and compliance rules that quietly block exporters), the penetration gap between current Indian share and total demand, active free-trade-agreement corridors that lower your landed cost, and the growth rate (CAGR) paired with volatility so you back steady demand, not a spike. For pharma, the non-tariff measures matter most: regulatory dossiers, GMP expectations and registration pathways differ across the European cluster, and getting them right is the difference between a market that opens and one that stalls.
Why now: the corridor is compounding in your favour
The European pharmaceutical corridor is growing, India's share is rising near 13 percent a year on the France line alone (Ministry of Commerce, FY2025-26), and global demand keeps climbing toward and past $910 billion (UN Comtrade). Steady, compounding corridors reward exporters who move early and build relationships before the field gets crowded. The makers who win the next decade of European pharma demand are the ones meeting verified buyers today, not the ones still posting listings and hoping. This is buyer generation, not lead generation: the goal is a real conversation with a real buyer who is ready to source from you.
How diipl finds your buyers
diipl runs a research-led buyer-generation engine built for exactly this. First, research-led precision: we score every target market on tariffs, non-tariff measures, penetration gaps, FTA corridors and growth-rate-versus-volatility, so your effort lands where your medicines actually win. Then we generate buyers through omni-channel outreach across LinkedIn, Google, email and WhatsApp, reaching active buyers with a message matched to your product and capacity. Every buyer is then verified for budget, authority, need and timeline before you ever speak, so you meet a verified buyer, never a cold name. Behind it all is a 16-plus year multilingual trade-veteran bench operating across 40-plus countries, the human moat most MSMEs cannot afford to hire, and 19M-plus buyer traction generated in-house. We guarantee the process: every buyer verified, every meeting earned through research. See exactly how it works on our export buyer generation page, and start with a free Custom Product Report on your own HS code to see which European markets your product should target first.
FAQ
Q: Which European countries import the most pharmaceuticals from India?
Europe is one of the strongest corridors for Indian pharma. Germany is the largest European importer at about $75 billion a year, followed by Switzerland at $67 billion, Belgium at $42 billion, France at $33 billion and Italy at $32 billion (UN Comtrade). India already exports about $635 million in pharmaceuticals to France and is growing near 13 percent a year there (Ministry of Commerce, FY2025-26), and the same opportunity pattern holds across the wider European cluster. diipl helps you pick the right one for your specific product.
Q: Can a small Indian MSME really export medicines to Europe?
Yes. India is known as the pharmacy of the world precisely because makers of every size contribute to generics, formulations and API supply. The barrier for an MSME is rarely demand, which is proven and large. It is finding the right buyers and meeting the regulatory and registration requirements of each market. diipl handles the research and the buyer generation so a focused manufacturer can compete on quality and price without building a costly export team first.
Q: What does diipl mean by a verified buyer?
A verified buyer is a buyer diipl has checked for budget, authority, need and timeline before you ever get on a call. It means the person you meet has the money, the decision-making power, a real requirement and a clear timeframe. This is buyer generation, not lead generation. Instead of sorting through cold names, you spend your time in genuine sourcing conversations. We guarantee the process: every buyer is verified before the meeting.
Q: How does diipl decide which export market I should target first?
diipl scores each market on the variables that actually decide success: import tariffs, non-tariff measures like registration and compliance rules, the penetration gap between India's current share and total demand, active free-trade-agreement corridors, and the growth rate paired with volatility. For pharmaceuticals, the regulatory and quality requirements weigh heavily. The aim is to point your capacity at markets with large, steady, growing demand where your product genuinely fits, not at one-time spikes.
Q: What is the free Custom Product Report for pharma exporters?
It is a research walkthrough built around your own product and HS code. A diipl research analyst reviews global and India trade data for your category, highlights the markets with the best mix of demand, growth and openness, and shows where verified buyers are most likely to be found. For a pharma maker weighing Germany versus France versus Belgium, it turns a big, intimidating opportunity into a clear, prioritised target list before you commit time or capacity.